SIRO Clinpharm, the international contract research organisation (CRO) with headquarters in Mumbai, India, continues to widen its reach in the Asia Pacific region, announcing a new alliance with Taiwan-based CRO Virginia Contract Research Organization Co, Ltd (VCRO).

In February, SIRO Clinpharm linked up with South Korea’s DreamCIS Inc, citing its goal of offering “a wider platform of patient recruitment capabilities from the Asia Pacific region for our global client base”.

VCRO has built up an “extensive network” in the Asia Pacific region, including a presence in Japan, China, Singapore and Hong Kong, noted general manager Chun-Chun Li.

Founded in 1997, the company provides a range of services compliant with International Conference on Harmonisation (ICH) Good Clinical Practice standards, including electronic data capture, interactive voice response systems and analytical laboratory capabilities.

Moreover, the market for clinical trials in Taiwan is “an attractive destination for global pharma-biotech firms”, said Chetan Tamhankar, chief executive officer of SIRO Clinpharm, pointing to the country’s “conducive regulatory environment and trained manpower”.

Already established in India, the US and Western and Central Europe, SIRO can now offer “wider geography and cost efficiencies to its existing and potential clients”, he commented.